Redeye provides a research update following Hoylu’s Q4 2022 report.
Redeye updates its estimates and fair value range following Tessin’s Q4 report.
Redeye provides an update on ChromoGenics following the company's Q4 results.
Redeye updates its fair value range following Alelion’s Q4 report, which was weaker than expected.
Redeye was hoping for a stronger finish to 2022 in terms of earnings.
Stockwik delivered a somewhat soft Q4 with a sales growth of 24% y/y, while EBITA declined 2% y/y, b...
Weaker end to 2022 than feared Re-setting growth expectations Still reasons to be optimistic for H2'...
Finding a new level of growth post COVID-19 Impressive profitability in Q4 Low churn confirmed, as e...
Adj. EBITDA SEK 5.4m vs. ABGSCe 0.2m Circular Energy very strong at SEK 38m sales (ABGSCe 18m) 12-6x...
Redeye comments on Mendus’ Q4 2022 report, with the company presenting a way forward for lead candid...
Cline Scientific publicerade den 17 februari 2023 bolagets helårsrapport för 2022 och visar på ytter...
Redeye updates its estimates for Mestro, which reported a strong Q4 2022, with an accelerated growth...
Kontraktstillverkarens starka tillväxt verkar hålla i sig och den långsiktiga trenden är helt klart ...
Tillväxt trots en tuff annonsmarknad Nettoomsättningen för helåret 2022 växte med 9% till 141 mkr (1...
Utmanande kvartal på grund av externa och interna faktorer Bokusgruppen rapporterade ett relativt sv...
Ett kvartal i linje med våra förväntningar Eolus rapporterade ett Q4’22 i stort i linje med våra för...
Redeye return with a research update following the Q4 report and recent progress in the company.
Redeye comments on the phase Ib study of PulmoStem that was completed before schedule.
Redeye states the report was in line with expectaions.
Redeye comments on Qlife’s rights issue announced yesterday evening.
